Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Goodwill & Intangibles: 2023-2025

Historic Goodwill & Intangibles for ARS Pharmaceuticals (SPRY) over the last 2 years, with Sep 2025 value amounting to $14.7 million.

  • ARS Pharmaceuticals' Goodwill & Intangibles rose 96.39% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 96.39%. This contributed to the annual value of $7.4 million for FY2024, which is 1094.65% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Goodwill & Intangibles stood at $14.7 million, which was up 13.54% from $13.0 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Goodwill & Intangibles registered a high of $14.7 million during Q3 2025, and its lowest value of $446,000 during Q2 2024.
  • Moreover, its 3-year median value for Goodwill & Intangibles was $7.3 million (2024), whereas its average is $6.4 million.
  • Data for ARS Pharmaceuticals' Goodwill & Intangibles shows a peak YoY surged of 2,808.52% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows ARS Pharmaceuticals' Goodwill & Intangibles stood at $617,000 in 2023, then soared by 1,094.65% to $7.4 million in 2024, then spiked by 96.39% to $14.7 million in 2025.
  • Its Goodwill & Intangibles was $14.7 million in Q3 2025, compared to $13.0 million in Q2 2025 and $7.2 million in Q1 2025.